• Home
  • News
  • Analysis
  •  
    Regions
    • South Asia
    • North America
    • Europe
    • Central Asia
    • Australasia
    • MENA
    • Southeast Asia
    • Greater China
    • North Asia
  •  
    Funds
    • LPs
    • Buyout
    • Growth
    • Venture
    • Renminbi
    • Secondary
    • Credit/Special Situations
    • Infrastructure
    • Real Estate
  •  
    Investments
    • Buyout
    • Growth
    • Credit
    • Early stage
    • PIPE
  •  
    Exits
    • Buyback
    • IPO
    • Open market
    • Trade sale
  •  
    Sectors
    • Real Estate
    • Consumer
    • Financials
    • Healthcare
    • Industrials
    • Infrastructure
    • Media
    • Technology
  • Events
  • Chinese edition
  • Data & Research
  • Weekly Digest
  • Newsletters
  • Sign in
  • Events
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)870 240 8859

      Email: customerservices@incisivemedia.com

      • Sign in
     
      • Saved articles
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • RSS
    • Twitter
    • LinkedIn
    • Newsletters
  • Free Trial
  • Subscribe
  • Weekly Digest
  • Chinese edition
  • Data & Research
    • Latest Data & Research
      2023-china-216x305
      Regional Reports

      The reports review the year's local private equity and venture capital activity and are filled with up-to-date data and intelligence on fundraising, investments, exits and M&A. The regional reports also feature information on key companies.

      Read more
      2016-pevc-cover
      Industry Review

      Asian Private Equity and Venture Capital Review provides an independent overview of the private equity, venture capital and M&A activities in the Asia region. It delivers insights on investments made, capital raised, sector specific figures and more.

      Read more
      AVCJ Database

      AVCJ Database is the ultimate link between Asian dealmakers and those who provide advisory, financial, legal and technological services to the private equity, venture capital and M&A industries. It is packed with facts and figures on more than 153,000 companies and almost 117,000 transactions.

      Read more
AVCJ
AVCJ
  • Home
  • News
  • Analysis
  • Regions
  • Funds
  • Investments
  • Exits
  • Sectors
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)870 240 8859

    Email: customerservices@incisivemedia.com

    • Sign in
 
    • Saved articles
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
AVCJ
  • Southeast Asia

Asia VCs invest $10m in US-Singapore biotech player

  • Justin Niessner
  • 01 February 2018
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Save this article  
  • Send to  

A group of VCs led by China’s 6 Dimensions Capital and Sino-US investor Danhua Capital (DHVC) has committed $10 million to US and Singapore-based Engine Biosciences.

Additional participants include EDBI, Pavilion Capital, Baidu Ventures, WI Harper, Nest.Bio Ventures, and biopharmaceutical technology provider WuXi AppTec. The oversubscribed round is being called the largest ever seed-stage investment in Southeast Asia.

Engine focuses on advanced biotechnology development, including the use of artificial intelligence (AI) and a genomics network biomedicine platform to help drug discovery processes. It will use the fresh capital to support a staff expansion across Singapore and San Francisco as well as preclinical studies with an unidentified US Fortune 500 partner.

"The lack of insight into complex and multi-factorial biological processes within cells contributes to the high failure rate across the drug development cycle," Leon Chen, CEO of 6 Dimensions, said in a statement. "Engine Biosciences has pioneered a new approach to address this by generating novel data and insights that are highly relevant to the biological process. We expect that the company's AI platform will lead to insightful information in complex diseases' pathways that was not previously possible using traditional wet lab-centric biology research."

The technology is currently being applied to a number of research areas related to new drug applications and the biological factors around targeted diseases. Engine claims to have achieved proof of concept across a number of disease indications and cell types, with active programs in the fields of cancer, neurodegeneration, autoimmune disorders, and skin.

Healthcare-focused 6 Dimensions Capital was formed last year through the merger of Frontline Bioventures and WuXi Healthcare Ventures. It has $1.6 billion of assets under management through four US dollar-denominated and three renminbi-denominated funds, along with a portfolio of more than 60 companies.

DHVC claims $600 million under management across three funds. Focus sectors include AI, virtual reality, augmented reality, mobile Internet, big data, cloud computing, wearable computing, robotics, and new materials with environmental or IT applications.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Save this article  
  • Send to  
  • Topics
  • Southeast Asia
  • Healthcare
  • Technology
  • Early-stage
  • Singapore
  • USA
  • 6 Dimensions Capital
  • EDBI
  • WI Harper Group
  • Pharmaceuticals

More on Southeast Asia

Singapore fintech start-up LXA gets $10m seed round
Singapore fintech start-up LXA gets $10m seed round
  • Southeast Asia
  • 10 November 2023
Reed Smith hires Sidley Austin's Asia fund formation leader
Reed Smith hires Sidley Austin's Asia fund formation leader
  • Southeast Asia
  • 02 November 2023
Polaris leads $27m round for Singapore's Engine Biosciences
Polaris leads $27m round for Singapore's Engine Biosciences
  • Southeast Asia
  • 01 November 2023
Deal focus: Algae-based bio-plastics come to Asia
Deal focus: Algae-based bio-plastics come to Asia
  • Southeast Asia
  • 01 November 2023

Latest News

Asian GPs slow implementation of ESG policies - survey
Asian GPs slow implementation of ESG policies - survey

Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...

  • GPs
  • 10 November 2023
Singapore fintech start-up LXA gets $10m seed round
Singapore fintech start-up LXA gets $10m seed round

New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.

  • Southeast Asia
  • 10 November 2023
India's InCred announces $60m round, claims unicorn status
India's InCred announces $60m round, claims unicorn status

Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”

  • South Asia
  • 10 November 2023
Insight leads $50m round for Australia's Roller
Insight leads $50m round for Australia's Roller

Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.

  • Australasia
  • 10 November 2023
Back to Top
  • About AVCJ
  • Advertise
  • Contacts
  • About ION Analytics
  • Terms of use
  • Privacy policy
  • Group disclaimer
  • RSS
  • Twitter
  • LinkedIn
  • Newsletters

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013